LITESPARK-012: Pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma Review

  

Authors:	Choueiri, T. K.; Powles, T.; Voss, M. H.; Plimack, E. R.; Gurney, H.; Song, Y.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
Review Title:	LITESPARK-012: Pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
Journal Title:	Future Oncology
Volume:	19
Issue:	40
ISSN:	1479-6694
Publisher:	Future Medicine
Date Published:	2023-12-01
Start Page:	2631
End Page:	2640
Language:	English
DOI:	10.2217/fon-2023-0283
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
PUBMED:	37882432
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=174425171&site=ehost-live&scope=site&custid=s2915669
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/212635